Cadence Pharmaceuticals Inc. v. Exela Pharma Sciences LLC
780 F.3d 1364
Fed. Cir.2015Background
- Cadence owns U.S. Patents No. 6,028,222 (’222) and No. 6,992,218 (’218) claiming methods and formulations for stabilizing aqueous acetaminophen (paracetamol) solutions.
- ’222 claims require acetaminophen in an aqueous medium with a buffering agent and a radical scavenger; ’218 claims a deoxygenation method to reduce dissolved oxygen below 2 ppm and optionally topping/stoppering under vacuum.
- Exela filed an ANDA seeking approval of a generic injectable acetaminophen and submitted Paragraph IV certifications challenging both patents. Cadence sued under 35 U.S.C. § 271(e)(2).
- The district court found the ’222 patent not invalid and literally infringed, and the ’218 patent not invalid and infringed under the doctrine of equivalents.
- Exela appealed claim construction for the ’222 patent, infringement findings for both patents (including DOE for the ’218 patent), and the district court’s non‑obviousness ruling for the ’218 patent.
Issues
| Issue | Plaintiff's Argument (Cadence) | Defendant's Argument (Exela) | Held |
|---|---|---|---|
| Construction of “buffering agent” (’222) | Plain meaning: an agent that helps resist pH change; does not require efficacy threshold | Term should require an effective concentration to prevent material pH change | Court: adopt plain meaning—"an agent that helps the formulation resist change in pH." |
| Infringement of ’222 claims | Exela’s sodium ascorbate functions as buffering agent and meets claim scope | Claim requires effective buffering concentration; Exela’s product doesn’t meet that threshold | Court: affirmed literal infringement under adopted construction. |
| Doctrine of equivalents for ’218 (timing of deoxygenation) | Timing is insubstantial; deoxygenating before vs after addition is equivalent because final O2 <2 ppm yields same stability | Timing is substantial; deoxygenating before addition is fundamentally different (antithesis) and cannot be equivalent | Court: affirmed DOE finding—testimony showed insubstantial difference and stability equivalence. |
| Construction of vacuum stoppering step (’218) | Step is mandatory based on specification and prosecution statements | Claim language makes topping/stoppering optional; prosecution did not clearly disclaim optionality | Court: vacuum stoppering is optional; affirmed infringement. |
| Obviousness of ’218 (in view of ’222 and Palmieri) | Palmieri teaches trace O2 improves stability; combining would make lowering to <2 ppm obvious | Palmieri concerns oxidation-prone pyrogallol, not acetaminophen (primarily hydrolysis); no motivation to combine; secondary considerations support non-obviousness | Court: affirmed non-obviousness—Exela failed to prove obviousness by clear and convincing evidence. |
Key Cases Cited
- Teva Pharm. USA, Inc. v. Sandoz, Inc., 135 S. Ct. 831 (2015) (standard of review for claim construction where factual findings are involved)
- Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005) (claims given their plain and ordinary meaning in view of intrinsic record)
- Graver Tank & Mfg. Co. v. Linde Air Prods. Co., 339 U.S. 605 (1950) (doctrine of equivalents analysis and insubstantial differences test)
- Graham v. John Deere Co., 383 U.S. 1 (1966) (framework for obviousness analysis)
- Microsoft Corp. v. i4i Ltd. P’ship, 131 S. Ct. 2238 (2011) (clear-and-convincing evidence standard to overcome patent validity)
- DePuy Spine, Inc. v. Medtronic Sofamor Danek, Inc., 469 F.3d 1005 (Fed. Cir. 2006) (explanation that “vitiation” is a legal conclusion tied to the factual equivalence analysis)